Citigroup
GLUE icon

Citigroup’s Monte Rosa Therapeutics GLUE Stock Holding History

Citigroup’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.13M Buy
129,467
+114,892
+788% +$2.17M ﹤0.01% 2561
2026
Q1 		$240K Buy
14,575
+3,889
+36% +$74.4K ﹤0.01% 3927
2025
Q4 		$168K Buy
10,686
+8,912
+502% +$120K ﹤0.01% 4075
2025
Q3 		$13.1K Sell
1,774
-21,139
-92% -$112K ﹤0.01% 4943
2025
Q2 		$103K Sell
22,913
-8,201
-26% -$36.6K ﹤0.01% 4387
2025
Q1 		$144K Sell
31,114
-13,769
-31% -$84.4K ﹤0.01% 4382
2024
Q4 		$311K Buy
44,883
+14,780
+49% +$111K ﹤0.01% 4130
2024
Q3 		$160K Buy
30,103
+20,565
+216% +$104K ﹤0.01% 4501
2024
Q2 		$35.7K Buy
9,538
+3,640
+62% +$18.6K ﹤0.01% 4777
2024
Q1 		$41.6K Buy
5,898
+1,500
+34% +$8.9K ﹤0.01% 4710
2023
Q4 		$24.8K Buy
4,398
+3,691
+522% +$14.5K ﹤0.01% 4896
2023
Q3 		$3.39K Sell
707
-10,271
-94% -$66.1K ﹤0.01% 4824
2023
Q2 		$75.2K Buy
10,978
+9,939
+957% +$64.3K ﹤0.01% 4380
2023
Q1 		$8.09K Sell
1,039
-301
-22% -$2.09K ﹤0.01% 4818
2022
Q4 		$10.2K Sell
1,340
-170
-11% -$1.42K ﹤0.01% 4833
2022
Q3 		$12K Sell
1,510
-1,675
-53% -$15.4K ﹤0.01% 4925
2022
Q2 		$31K Buy
3,185
+690
+28% +$6.93K ﹤0.01% 4775
2022
Q1 		$35K Sell
2,495
-2,308
-48% -$32K ﹤0.01% 4889
2021
Q4 		$98K Buy
4,803
+3,482
+264% +$72.9K ﹤0.01% 4743
2021
Q3 		$29K Buy
+1,321
New +$37.9K ﹤0.01% 5048

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citigroup's GLUE Position: Q2 2026 in Review

Citigroup increased its Monte Rosa Therapeutics (GLUE) stake by 788% in Q2 2026, buying an estimated $2.17M and bringing the position to 129,467 shares worth $3.13M. The position accounts for ﹤0.01% of the portfolio, ranked #2561.

Citigroup first reported a position in GLUE in Q3 2021 and has held it in 20 quarters since. 192 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Citigroup held 129,467 shares of Monte Rosa Therapeutics worth $3.13M as of Q2 2026.
  • Citigroup bought 114,892 Monte Rosa Therapeutics shares in Q2 2026, an estimated $2.17M.
  • Monte Rosa Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #2561 holding.
  • Citigroup first reported a position in Monte Rosa Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • 192 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.